KR890004681A - 피부투과 치료계 - Google Patents

피부투과 치료계 Download PDF

Info

Publication number
KR890004681A
KR890004681A KR1019880011332A KR880011332A KR890004681A KR 890004681 A KR890004681 A KR 890004681A KR 1019880011332 A KR1019880011332 A KR 1019880011332A KR 880011332 A KR880011332 A KR 880011332A KR 890004681 A KR890004681 A KR 890004681A
Authority
KR
South Korea
Prior art keywords
treatment system
skin permeation
moxonidine
permeation treatment
lauric acid
Prior art date
Application number
KR1019880011332A
Other languages
English (en)
Inventor
구제 귄터
호르스트만 미하엘
에어레르 악셀
Original Assignee
그뤼츠너 딘네
바이어스도르프 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 그뤼츠너 딘네, 바이어스도르프 악티엔게젤샤프트 filed Critical 그뤼츠너 딘네
Publication of KR890004681A publication Critical patent/KR890004681A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

피부투과 치료제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 비교 실시예 1과 비교하여 버퍼용액에 의해 단위면적당 흡수된 목소니딘의 양을 나타낸 도.
제2도는 비교 실시예 1과 비교하여 평방센티미터당 경고의 흡수율을 나타낸 도.

Claims (9)

  1. 투과촉진제로서 적어도 C12를 가지는 적어도 하나의 고급 n-알칸 카복실산을 함유하는, 목소니딘의 투여를 위한 피부투과 치료계.
  2. 제1항에 있어서, 이 계가 매트릭스 형태의 자가-접착 경고임을 특징으로 하는 피부투과 치료계.
  3. 제2항에 있어서, 임의로 가교된 아크릴레이트에 근거하거나 도는 폴리이소부텐 및 합성탄화수소 수지에 근거한 자가접착 조성물을 함유함을 특징으로 하는 조성물.
  4. 제2항에 있어서, 목소니딘 및 라우린산을 함유함을 특징으로 하는 피부투과 치료계.
  5. 제4항에 있어서, 목소니딘이 미분화됨을 특징으로 하는 피부투과 치료계.
  6. 제4항에 있어서, 목소니딘 중량부당 1-2중량부의 라우린산을 함유함을 특징으로 하는 피부투과 치료계.
  7. 제2항에 있어서, 평방미터당 5-10g의 목소리딘 및 7-20g의 라우린산, 특히 5-10g의 목소니딘 및 7-15g의 라우린산을 함유함을 특징으로 하는 피부투과 치료계.
  8. 몇일간 고혈압의 치료를 위해 제1-7항 중의 한 항에 따르는 피부투과 치료계의 사용방법.
  9. 목소니딘이 미세하게 분할된 형태로 적어도 C12를 가지는 적어도 하나의 n-알칸 카복실산과 함께 계 내로 통합됨을 특징으로 하는 제1-7항중의 한항에 따르는 피부투과 치료계의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880011332A 1987-09-02 1988-09-02 피부투과 치료계 KR890004681A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19873729299 DE3729299A1 (de) 1987-09-02 1987-09-02 Transdermales therapeutisches system
DEP3729299.4 1987-09-02

Publications (1)

Publication Number Publication Date
KR890004681A true KR890004681A (ko) 1989-05-09

Family

ID=6335050

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880011332A KR890004681A (ko) 1987-09-02 1988-09-02 피부투과 치료계

Country Status (9)

Country Link
US (1) US4882163A (ko)
EP (1) EP0305726B1 (ko)
JP (1) JPS6470415A (ko)
KR (1) KR890004681A (ko)
AT (1) ATE74001T1 (ko)
AU (1) AU2060688A (ko)
DE (2) DE3729299A1 (ko)
ES (1) ES2032905T3 (ko)
ZA (1) ZA885944B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102274435B1 (ko) * 2020-12-04 2021-07-08 시스킨코리아(주) 피부 투과 향상을 위한 유동성을 갖는 미세 수중유 에멀전 조성물

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629019A (en) * 1992-02-27 1997-05-13 Alza Corporation Formulations with hydrophobic permeation enhancers
AU3942193A (en) * 1992-03-31 1993-11-08 Tbs Laboratories, Inc. Transdermal albuterol absorption dosage unit and process
DE19500662C2 (de) * 1995-01-12 2001-04-26 Lohmann Therapie Syst Lts Estradiolhaltiges Pflaster und seine Verwendung
CA2212294A1 (en) * 1995-02-28 1996-09-06 Beiersdorf-Lilly Gmbh Use of moxonidine for the treatment of atherosclerosis
US5990179A (en) * 1995-04-28 1999-11-23 Alza Corporation Composition and method of enhancing electrotransport agent delivery
US5985316A (en) * 1995-04-28 1999-11-16 Alza Corporation Composition and method of enhancing electrotransport agent delivery
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal
WO1997046241A1 (en) * 1996-06-06 1997-12-11 Eli Lilly And Company Formulation and method for treating congestive heart failure
DE19706824C1 (de) * 1997-02-21 1998-03-26 Lohmann Therapie Syst Lts Transdermales oder topisches Plastersystem mit Polyacrylatmatrix mit verbesserten physikalischen Eigenschaften
DE10019311A1 (de) * 2000-04-19 2001-10-31 Lohmann Therapie Syst Lts Transdermale therapuetische Systeme zur Applikation von Moxonidin
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
US20050208117A1 (en) * 2001-03-16 2005-09-22 Venkatraman Subramanian S Transdermal administration of fentanyl and analogs thereof
WO2002074286A1 (en) * 2001-03-16 2002-09-26 Alza Corporation Transdermal patch for administering fentanyl
US20020198210A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Alpha-2-adrenergic agonist/fatty acid compositions
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
WO2002089853A2 (en) * 2001-05-03 2002-11-14 Allergan, Inc. Compositions having enhanced pharmacokinetic characteristics
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
DE102006054732B4 (de) * 2006-11-21 2010-12-30 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit Ionenpaar-Mikroreservoiren
RU2499583C2 (ru) * 2007-10-15 2013-11-27 Алза Корпорейшн Заместительное трансдермальное введение фентанила один раз в день
DE102009013469B4 (de) 2009-03-19 2014-04-17 Bubbles And Beyond Gmbh Zubereitung zur äußerlichen Anwendung

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
DK243084A (da) * 1983-05-26 1984-11-27 Takeda Chemical Industries Ltd Perkutane farmaceutiske praeparater til udvortes brug
EP0169364B1 (de) * 1984-06-23 1988-08-03 Beiersdorf Aktiengesellschaft Selbstklebendes Pflaster
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
IL72684A (en) * 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
CA1288698C (en) * 1985-08-30 1991-09-10 Yie W. Chien Transdermal anti-anginal pharmaceutical dosage
DE3617158C2 (de) * 1986-05-22 1994-10-06 Lohmann Therapie Syst Lts Transdermales Arzneimittel

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102274435B1 (ko) * 2020-12-04 2021-07-08 시스킨코리아(주) 피부 투과 향상을 위한 유동성을 갖는 미세 수중유 에멀전 조성물

Also Published As

Publication number Publication date
EP0305726B1 (de) 1992-03-25
ES2032905T3 (es) 1993-03-01
ATE74001T1 (de) 1992-04-15
DE3869520D1 (en) 1992-04-30
JPS6470415A (en) 1989-03-15
EP0305726A1 (de) 1989-03-08
US4882163A (en) 1989-11-21
ZA885944B (en) 1989-06-28
DE3729299A1 (de) 1989-03-23
AU2060688A (en) 1989-03-02

Similar Documents

Publication Publication Date Title
KR890004681A (ko) 피부투과 치료계
US5091171B1 (en) Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use
ES2000428T3 (es) Procedimiento para producir un medicamento para el tratamiento de la enfermedad de alzheimer, que contiene galantamina, y dispositivo medico correspondiente.
KR950031058A (ko) 경피 흡수 제제
BR9307754A (pt) Composições farmacêuticas para penetração na pele
ES2089954B1 (es) Metodo para preparar una emulsion de hidrocarburo viscoso en solucion tampon acuosa.
DE3881340T2 (de) Vorrichtung zur transdermalen applikation von medikamenten.
SE8801185L (sv) Transdermalt, terapeutiskt system
KR900700128A (ko) 외상 치료법
NO951592D0 (no) Fremgangsmåte for fremstilling av et transdermalt terapeutisk system
AR246755A1 (es) Una composicion para el tratamiento de las superficies de los suelos.
ES2045069T3 (es) Pelicula polimerica silenciosa y recipientes para uso medico con ella fabricados.
KR890700026A (ko) 건선 치료에 있어서 주석 프로토포르피린 및 주석 메조포르피린의 용도
DE69133077T2 (de) Herstellung von ST1435 enthaltenden pharmazeutischen Zusammensetzungen zur topischen Verwendung
KR900011458A (ko) 항 종양성 활성 물질인 5- 플루오로우라실을 함유하는 표재성 치료 시스템
KR850000968A (ko) 피부 보호 조성물의 제조 방법
PT90127A (pt) Processo para a preparacao de composicoes farmaceuticas com accao analgesica que contem 4-aril-4-piperidino (ou pirrolidino ou hexa-hidroazepino)-carbinois ou os seus analogos heterociclicos
EP0267293A4 (en) PRE-TREATMENT ACTIVE INGREDIENT FOR PERCUTANEOUS ADMINISTRATION.
KR940008678A (ko) 주사용 메스나 액제
KR890007728A (ko) 진통제 제조방법
AR241513A1 (es) Procedimiento de preparacion de una composicion farmaceutica para absorcion percutanea.
KAMIKAWA et al. Laser Surgical Unit
KR880000094A (ko) 위염치료제
KR900017592A (ko) Tnf의 부작용을 감소시키기 위한 용도 및 약제
KR910700313A (ko) 트랜스-4,4′-스틸벤디카복실산과 1.6-헥산디올로 만든 폴리에스테르와 폴리카보네이트의 혼합물

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid